New Leadership Steps in as Praxis Prepares for Potential Brain Drug Launches

Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments - Praxis Precision Medicine (NASDAQ:PRAX)

BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation–inhibition imbalance, today announced the appointment of Jeffrey B. Kindler and Stuart Arbuckle to its board of directors, and the promotions of Megan Sniecinski to Chief Op…

New leadership steps in as Praxis prepares for potential brain drug launches

Praxis Precision Medicines adds ex-Pfizer CEO Jeffrey Kindler and former Vertex COO Stuart Arbuckle to its board while promoting two internal R&D leaders.